Tiziana Life Sciences has dosed the first patient in a Phase 2a clinical trial testing its foralumab nasal spray in people with nonactive secondary progressive multiple sclerosis (SPMS).
The trial will include about 54 participants, enrolled across six clinical sites. Patients will be randomly assigned to receive one of two doses of foralumab or a placebo, and neither investigators nor patients will know which treatment they are receiving. Early data is expected by the end of 2024. Read more HERE…